PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

Explore the recent developments and clinical updates on PARP inhibitors in the management of ovarian cancer.
With Dr Susana Banerjee, Dr Domenica Lorusso and Prof. Frederik Marme.
Watch now: touchoncology.com/education/c...
--------
This activity is funded by an independent medical education grant from GlaxoSmithKline and is provided by touchIME.

[@jdakat88]

Thank you so much for sharing this.

[@2gwailo]

I think it is worth pointing out that you had said IDS/NAC is worse than PDS via GORILLA-3004. Which states this is true for non-BRCAm patients. In BRCAm patients, the only independent risk factor found was CA-125>26/4U/mL. Just saying the blanket statement in the video is a bit misleading.